DCVax-Brain: Updated Phase I/II data

Updated pooled data from 20 patients in U.S. Phase I and Phase I/II trials of DCVax-Brain plus standard of care (SOC) to treat newly-diagnosed GBM showed that no patients died from Oct. 1, 2009 through July 1, 2010. Overall, 5 (25%) patients were alive at July 1, with 33% and 27% of patients achieving 4- and >=6-year survival, respectively. Median OS was 3 years and the longest surviving patient to date has exceeded 10 years. ...